Makindo Medical Notes"One small step for man, one large step for Makindo" |
|
---|---|
Download all this content in the Apps now Android App and Apple iPhone/Pad App | |
MEDICAL DISCLAIMER: The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis, or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd. |
Related Subjects: |Emergency Drugs |Emergency Drug Antidotes |Emergency Cardiac Drugs |Emergency Endocrine Drugs |Emergency Gastrointestinal Drugs |Emergency Haematology Drugs |Emergency Neuropsychiatric drugs |Emergency Pain drugs |Emergency Respiratory drugs |Emergency Obstetric and Gynaecology Drugs |Emergency Paediatric Drugs
DRUG (UK Name) | MOA | DOSE IV | DOSE PO | INDICATION | CONTRAINDICATION / CAUTION |
---|---|---|---|---|---|
Diazepam | Enhances inhibitory effects of GABA at benzodiazepine receptors | 2–10 mg IV/IM every 6 h PRN | 2–10 mg PO every 6 h PRN | Seizure management, alcohol withdrawal, agitation, muscle spasm | Respiratory depression, hypotension, caution in pregnancy (Preg D) |
Droperidol | Dopamine and alpha receptor antagonist | 1.25–2.5 mg IV every 4 h PRN | N/A | Antiemetic, treatment of migraine-associated nausea | QT prolongation (risk of Torsades), NMS, EPS; caution in pregnancy (Preg C) |
Fosphenytoin | Prodrug of phenytoin; stabilises neuronal Na+ channels, stopping seizure activity | 15–20 mg PE/kg IV loading at ≤150 mg PE/min (PE = phenytoin equivalents) | N/A | Status epilepticus | Rapid infusion can cause hypotension/dysrhythmias; monitor ECG and BP, caution in pregnancy (Preg D) |
Haloperidol | Dopamine receptor antagonist (D1/D2) | 5–10 mg PO/IM/IV every 2 h PRN (max 100 mg/day) | N/A | Agitation, psychosis | Dementia-related psychosis, NMS, EPS, QT prolongation; caution in pregnancy (Preg C) |
Ketamine | NMDA receptor antagonist providing dissociative anaesthesia |
Subdissociative: 0.1–0.5 mg/kg IV
Procedural sedation: 0.5–1 mg/kg IV RSI induction: ~2 mg/kg IV |
N/A | Analgesia, sedation, RSI induction | Emergence reactions (may use benzodiazepines), laryngospasm, raised IOP/ICP, tachycardia, hypertension; caution in pregnancy (Preg D) |
Methohexital | Ultra-short acting barbiturate producing sedation and hypnosis | 1 mg/kg IV, then 0.5 mg/kg every 2–5 min PRN | N/A | Procedural sedation | Laryngospasm (treat with additional methohexital), respiratory depression, hypotension; caution in pregnancy (Preg B) |
Midazolam | Enhances inhibitory effects of GABA (benzodiazepine) |
RSI: ~0.1 mg/kg IV
Infusion: 1–10 mg/h Procedural sedation: 0.02–0.04 mg/kg IV |
N/A | Seizure control, procedural sedation, ventilator sedation, RSI induction | Respiratory depression, hypotension; caution in pregnancy (Preg D) |
Nimodipine | Calcium channel blocker selective for cerebral arteries | N/A | 60 mg PO every 4 h | Prevention of vasospasm post subarachnoid haemorrhage | Hypotension; caution in pregnancy (Preg C) |
Olanzapine | Antagonist at dopamine, histamine, alpha1, and 5-HT2 receptors | 5–10 mg IM/day (max 30 mg/day) | 5–10 mg ODT/day (max 30 mg/day) | Agitation, psychosis | Not for dementia-related psychosis, NMS, EPS, orthostatic hypotension, QT prolongation; no IV form; caution in pregnancy (Preg C) |
DRUG (UK Name) | MOA | DOSE IV | DOSE PO | INDICATION | CONTRAINDICATION / CAUTION |
---|---|---|---|---|---|
Lorazepam | Enhances inhibitory effects of GABA (benzodiazepine) | Bolus: 1–2 mg IV
Infusion: 1–10 mg/h |
N/A | Delirium tremens, status epilepticus, serotonin syndrome, agitation | Respiratory depression, hypotension; caution in pregnancy (Preg D) |
Mannitol | Osmotic diuretic increasing plasma osmolarity, reducing ICP | 1 g/kg IV once (may be repeated as per protocol) | N/A | Elevated ICP, impending cerebral herniation | May cause dehydration, electrolyte imbalance, osmotic nephrosis |
Phenobarbital | Barbiturate causing sedation, hypnosis, and can suppress seizures | 20 mg/kg IV loading; may repeat 5–10 mg/kg in 20 min (max 30 mg/kg total); max infusion 50 mg/min | N/A | Status epilepticus | Respiratory depression, hypotension; caution in pregnancy (Preg D) |
Levetiracetam (Keppra) | Modulates SV2A protein and inhibits neurotransmitter release, preventing seizures | 20–40 mg/kg IV loading (often 1–2 g IV over ~15 min) | 500–1500 mg PO twice daily (adjust dose per response) | Seizure prophylaxis and treatment | Generally well-tolerated; sedation, irritability, rare psychosis; caution in pregnancy (Preg C) |
Phenytoin | Stabilises voltage-dependent neuronal Na+ channels |
Loading: 15–20 mg/kg IV at ≤50 mg/min
Maintenance: ~100 mg IV every 6–8 h |
~100 mg PO three times daily (adjust based on levels) | Status epilepticus, seizure prophylaxis | Hypotension, arrhythmias with rapid infusion, CNS side effects (nystagmus, ataxia), CYP interactions; caution in pregnancy (Preg D) |